Urinary tract infection (UTI) is one of the most prevalent health issues in most people. UTI is more common in women as compared to men, as women face health complications such as menopause, pregnancy, and certain side effects of birth control measures. However, on a global level, the urinary tract infection treatment market is challenged, as individuals are hesitant to consult doctors and healthcare providers for appropriate diagnosis.
Ongoing research and development activities in the urinary tract infection treatment market suggest the predictive factors of multidrug-resistant gram-negative bacteria in hospitalized patients suffering from complicated urinary tract infection (cUTI). Stakeholders are using the mixed-effects logistic regression model to study the symptoms in patients. Results show that, the antibiotic resistance for gram-negative bacteria is high in patients suffering from cUTI. Thus, appropriate diagnosis with healthcare providers and active enforcement of antibiotic stewardship policies will reduce the incidences of multi-drug antibiotic abstinence in patients for the treatment for complicated urinary tract infection.
To know the scope of our report Get a Sample on Urinary Tract Infection Treatment Market
Patients with renal diseases are more susceptible to the risk of being exposed to urinary tract infection, due to long stays in the hospital, non-sanitized urinary catheters, and manipulations caused during urological treatment. As a result, healthcare providers in the urinary tract infection treatment market need to broaden the monitoring measures for patients, post-hospitalization, to reduce the incidences of urinary tract infection. Market players can create awareness in patients to carefully use urinary catheters and avoid unnecessary catheterization in patients.
On the other hand, healthcare providers are encountering increased incidences of community-acquired urinary tract infection caused by the escherichia coli (E. Coli) pathogen due to antibiotic resistance in patients. Thus, stakeholders in the urinary tract infection treatment market must cater to the growing need for effective antibiotic medication for UTI caused due to the E. Coli pathogen.
Get a glimpse of the in-depth analysis through our Report Brochure
Stakeholders in the UTI treatment market are developing new smartphone apps designed for women. These apps are created by on-boarding several doctors and pharmacies. With the growing influx of digitization in the healthcare industry, stakeholders can eliminate the issue of long-queue appointments with general practitioners for individuals. With effective diagnosis from doctors through the app, doctors can prescribe the right medication for the treatment of urinary tract infection, and pharmacists can supply home-testing kits and other medicinal antibiotics on demand. This digitization phenomena has created a win-win situation for stakeholders and healthcare providers, as well as pharmacists.
One of the biggest challenges that stakeholders operating in the urinary tract infection treatment market are facing is the antibiotic resistance for the treatment of urinary tract infection, even in healthy individuals with strong immune systems. As such, they are tackling the issue of antibiotic resistance with high-end antibiotics. Players operating in the urinary tract infection treatment market are also developing cost-effective solutions such as instant urine cultures to assess the resistance levels of individuals for antibiotics. For instance, in November 2018, Allergan — a leading pharmaceutical company, announced the launch of the FDA accepted supplemental drug ? AVYCAZ, for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections, for patients between the age group of 3 months to 18 years.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint on the UTI Treatment Market
Analysts of the urinary tract infection treatment market portray a promising future for stakeholders during the forecast period of 2019-2027. Market players need to focus on innovating treatment options for urinary tract infection catering to complicated urinary tract infection, as currently cUTI accounts for ~82% of the market value share. Manufacturers in the UTI treatment market can build strategic tie-ups with hospital pharmacists, as they dominate the market value share, amounting to ~47%, though, retail pharmacists will have high growth potential in the coming years. Market players are challenged with high antibiotic resistance in UTI patients. This challenge can be overcome with increased offerings for at-home instant urine culture tests and the development of smartphone apps.
Prominent players operating in the urinary tract infection treatment market include
Key players in the global urinary tract infection treatment market engage in new product development and approvals, key mergers & acquisitions, and collaborations. These strategies by industry players are likely to augment the global urinary tract infection treatment market. Some developments in the global urinary tract infection treatment market are as follows:
In the global urinary tract infection treatment market report, we have discussed individual strategies, followed by company profiles of the manufacturers of urinary tract infection products. The ‘Competitive Landscape’ section is included in the market report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global urinary tract infection treatment market.
Urinary Tract Infection Treatment Market - Segmentation
The comprehensive study on the urinary tract infection treatment market provides a comprehensive analysis of the market attractiveness by offering insights into the key segments. The urinary tract infection treatment market has been segregated on the basis of disease, drug class, pathogen, source of infection, gender, distribution channel, and region. The global study highlights a country-wise analysis to lend incisive insights about the healthcare innovations of urinary tract infection treatments.
Each of the segments included in this report help in gaining crucial insights into the urinary tract infection treatment market. The study on the urinary tract infection treatment market offers historical, current, and futuristic trends influencing its growth. In addition to this, it covers value chain analysis, Y-o-Y growth analysis, and supply chain analysis.
|
Disease |
Uncomplicated UTI Complicated UTI |
|
Drug Class |
Quinolones Beta-lactams Macrolides Aminoglycosides Others |
|
Pathogen |
E. Coli Pseudomonas aeruginosa Enterococcus spp K. pneumoniae S. aureus Others |
|
Source of Infection |
Hospital-acquired UTI Community-acquired UTI |
|
Gender |
Female Male |
|
Distribution Channel |
Retail Pharmacies Hospital Pharmacies Online Pharmacies |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa
|
The urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018
Urinary tract infection treatment market is expected to touch US$ 7.5 Bn in 2027
Urinary tract infection treatment market to expand at a CAGR of ~3% from 2019 to 2027
Urinary tract infection treatment market is driven by rise in the awareness about urinary tract infection among women
Key players in the urinary tract infection treatment market include Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Urinary Tract Infection Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1 Rise in prevalence of UTI
4.3.1.2. Increase in number of hospital acquired infection
4.3.1.3. Rise in awareness about women's health
4.3.1.4. Introduction of new diagnostic test
4.3.1.5. Development of new antibiotics
4.3.2. Restraints
4.3.2.1 Introduction of generic drug
4.3.2.2. Patent Expiry
4.3.3. Opportunities
4.4. Global Urinary Tract Infection Treatment Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Epidemiology Overview of UTI by Key Countries (Prevalence, Incidence, Overall Burden)
5.2. Pipeline Analysis
5.3. Overview of Guidelines for Diagnosis & Treatment of UTI’s
5.4. Reimbursement Scenario
5.5. Overview of Multi-Drug Resistance Pathogen and Infections (Infection Types & Prevalence, Most drug resistant Bacterial Strains)
5.6. Advancements in UTI diagnosis (Rapid Action Tests, New Assays in Anti-microbial susceptibility testing, etc.)
6. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Disease
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease, 2017–2027
6.3.1. Uncomplicated UTI
6.3.2. Complicated UTI
6.4. Market Attractiveness, by Disease
7. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2017–2027
7.3.1. Quinolones
7.3.2. Beta-lactams
7.3.3. Macrolides
7.3.4. Aminoglycosides
7.3.5. Others
7.4. Market Attractiveness, by Drug Class
8. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Pathogen
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Pathogen, 2017–2027
8.3.1. E. coli
8.3.2. Pseudomonas aeruginosa
8.3.3. Enterococcus spp
8.3.4. K. pneumoniae
8.3.5. S. aureus
8.3.6. Others
8.4. Market Attractiveness, by Pathogen
9. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Source of Infection
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Source of Infection, 2017–2027
9.3.1. Hospital Acquired UTI
9.3.2. Community Acquired UTI
9.4. Market Attractiveness, by Source of Infection
10. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Gender
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Gender, 2017–2027
10.3.1. Female
10.3.2. Male
10.4. Market Attractiveness, by Gender
11. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by Distribution Channel, 2017–2027
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness, by Distribution Channel
12. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness, by Country/Region
13. North America Urinary Tract Infection Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease, 2017–2027
13.2.1. Uncomplicated UTI
13.2.2. Complicated UTI
13.3. Market Value Forecast, by Drug Class, 2017–2027
13.3.1. Quinolones
13.3.2. Beta-lactams
13.3.3. Macrolides
13.3.4. Aminoglycosides
13.3.5. Others
13.4. Market Value Forecast, by Pathogen, 2017–2027
13.4.1. E. coli
13.4.2. Pseudomonas aeruginosa
13.4.3. Enterococcus spp
13.4.4. K. pneumoniae
13.4.5. S. aureus
13.4.6. Others
13.5. Market Value Forecast, by Source of Infection, 2017–2027
13.5.1. Hospital Acquired UTI
13.5.2. Community Acquired UTI
13.6. Market Value Forecast, by Gender, 2017–2027
13.6.1. Female
13.6.2. Male
13.7. Market Value Forecast, by Distribution Channel, 2017–2027
13.7.1. Retail Pharmacies
13.7.2. Hospital Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast, by Country, 2017–2027
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Disease
13.9.2. By Drug Class
13.9.3. By Pathogen
13.9.4. By Source of Infection
13.9.5. By Gender
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Urinary Tract Infection Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease, 2017–2027
14.2.1. Uncomplicated UTI
14.2.2. Complicated UTI
14.3. Market Value Forecast, by Drug Class, 2017–2027
14.3.1. Quinolones
14.3.2. Beta-lactams
14.3.3. Macrolides
14.3.4. Aminoglycosides
14.3.5. Others
14.4. Market Value Forecast, by Pathogen, 2017–2027
14.4.1. E. coli
14.4.2. Pseudomonas aeruginosa
14.4.3. Enterococcus spp
14.4.4. K. pneumoniae
14.4.5. S. aureus
14.4.6. Others
14.5. Market Value Forecast, by Source of Infection, 2017–2027
14.5.1. Hospital Acquired UTI
14.5.2. Community Acquired UTI
14.6. Market Value Forecast, by Gender, 2017–2027
14.6.1. Female
14.6.2. Male
14.7. Market Value Forecast, by Distribution Channel, 2017–2027
14.7.1. Retail Pharmacies
14.7.2. Hospital Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast, by Country/Sub-region, 2017–2027
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Disease
14.9.2. By Drug Class
14.9.3. By Pathogen
14.9.4. By Source of Infection
14.9.5. By Gender
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Urinary Tract Infection Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease, 2017–2027
15.2.1. Uncomplicated UTI
15.2.2. Complicated UTI
15.3. Market Value Forecast, by Drug Class, 2017–2027
15.3.1. Quinolones
15.3.2. Beta-lactams
15.3.3. Macrolides
15.3.4. Aminoglycosides
15.3.5. Others
15.4. Market Value Forecast, by Pathogen, 2017–2027
15.4.1. E. coli
15.4.2. Pseudomonas aeruginosa
15.4.3. Enterococcus spp
15.4.4. K. pneumoniae
15.4.5. S. aureus
15.4.6. Others
15.5. Market Value Forecast, by Source of Infection, 2017–2027
15.5.1. Hospital Acquired UTI
15.5.2. Community Acquired UTI
15.6. Market Value Forecast, by Gender, 2017–2027
15.6.1. Female
15.6.2. Male
15.7. Market Value Forecast, by Distribution Channel, 2017–2027
15.7.1. Retail Pharmacies
15.7.2. Hospital Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast, by Country/Sub-region, 2017–2027
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Disease
15.9.2. By Drug Class
15.9.3. By Pathogen
15.9.4. By Source of Infection
15.9.5. By Gender
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Urinary Tract Infection Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Disease, 2017–2027
16.2.1. Uncomplicated UTI
16.2.2. Complicated UTI
16.3. Market Value Forecast, by Drug Class, 2017–2027
16.3.1. Quinolones
16.3.2. Beta-lactams
16.3.3. Macrolides
16.3.4. Aminoglycosides
16.3.5. Others
16.4. Market Value Forecast, by Pathogen, 2017–2027
16.4.1. E. coli
16.4.2. Pseudomonas aeruginosa
16.4.3. Enterococcus spp
16.4.4. K. pneumoniae
16.4.5. S. aureus
16.4.6. Others
16.5. Market Value Forecast, by Source of Infection, 2017–2027
16.5.1. Hospital Acquired UTI
16.5.2. Community Acquired UTI
16.6. Market Value Forecast, by Gender, 2017–2027
16.6.1. Female
16.6.2. Male
16.7. Market Value Forecast, by Distribution Channel, 2017–2027
16.7.1. Retail Pharmacies
16.7.2. Hospital Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast, by Country/Sub-region, 2017–2027
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Disease
16.9.2. By Drug Class
16.9.3. By Pathogen
16.9.4. By Source of Infection
16.9.5. By Gender
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Urinary Tract Infection Treatment Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Disease, 2017–2027
17.2.1. Uncomplicated UTI
17.2.2. Complicated UTI
17.3. Market Value Forecast, by Drug Class, 2017–2027
17.3.1. Quinolones
17.3.2. Beta-lactams
17.3.3. Macrolides
17.3.4. Aminoglycosides
17.3.5. Others
17.4. Market Value Forecast, by Pathogen, 2017–2027
17.4.1. E. coli
17.4.2. Pseudomonas aeruginosa
17.4.3. Enterococcus spp
17.4.4. K. pneumoniae
17.4.5. S. aureus
17.4.6. Others
17.5. Market Value Forecast, by Source of Infection, 2017–2027
17.5.1. Hospital Acquired UTI
17.5.2. Community Acquired UTI
17.6. Market Value Forecast, by Gender, 2017–2027
17.6.1. Female
17.6.2. Male
17.7. Market Value Forecast, by Distribution Channel, 2017–2027
17.7.1. Retail Pharmacies
17.7.2. Hospital Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast, by Country/Sub-region, 2017–2027
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Disease
17.9.2. By Drug Class
17.9.3. By Pathogen
17.9.4. By Source of Infection
17.9.5. By Gender
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis/Ranking, by Company, 2018
18.3. Company Profiles
18.3.1. Allergan
18.3.1.1. Company Overview
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Financial Overview
18.3.1.5. Strategic Overview
18.3.2. Bayer AG
18.3.2.1. Company Overview
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Financial Overview
18.3.2.5. Strategic Overview
18.3.3. Pfizer, Inc.
18.3.3.1. Company Overview
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Financial Overview
18.3.3.5. Strategic Overview
18.3.4. GlaxoSmithKline plc
18.3.4.1. Company Overview
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Financial Overview
18.3.4.5. Strategic Overview
18.3.5. Bristol-Myers Squibb Company
18.3.5.1. Company Overview
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Financial Overview
18.3.6. Johnson & Johnson (Janssen Global Services, LLC)
18.3.6.1. Company Overview
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Financial Overview
18.3.6.5. Strategic Overview
18.3.7. LUPIN
18.3.7.1. Company Overview
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Financial Overview
18.3.7.5. Strategic Overview
18.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
18.3.8.1. Company Overview
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Financial Overview
18.3.8.5. Strategic Overview
18.3.9. Dr. Reddy’s Laboratories Ltd
18.3.9.1. Company Overview
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Financial Overview
18.3.10. Almirall, S.A
18.3.10.1. Company Overview
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Financial Overview
18.3.10.5. Strategic Overview
List of Tables
Table 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 04: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 05: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 06: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 09: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 11: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 12: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 13: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 16: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 18: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 19: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 23: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 25: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 26: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 27: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 30: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 31: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 32: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 33: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 34: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 35: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 37: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 39: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 40: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 41: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 42: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figures
Figure 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn), by Pathogen, 2018
Figure 03: Market Snapshot - Top 2 Trends
Figure 04: Market Overview
Figure 05: Global Urinary Tract Infection Treatment Market Value Share, by Disease, 2018
Figure 06: Global Urinary Tract Infection Treatment Market Value Share, by Drug Class, 2018
Figure 07: Global Urinary Tract Infection Treatment Market Value Share, by Pathogen, 2018
Figure 08: Global Urinary Tract Infection Treatment Market Value Share, by Source of Infection, 2018
Figure 09: Global Urinary Tract Infection Treatment Market Value Share, by Gender, 2018
Figure 10: Global Urinary Tract Infection Treatment Market Value Share, by Distribution Channel, 2018
Figure 11: Global Urinary Tract Infection Treatment Value Share, by region, 2018
Figure 12: Global Urinary Tract Infection Treatment Market Value Share, by Region, 2018
Figure 13: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 14: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 15: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Uncomplicated UTI, 2017–2027
Figure 16: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Complicated UTI, 2017–2027
Figure 17: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2018–2027
Figure 18: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 19: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Quinolones, 2017–2027
Figure 20: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Beta-lactams, 2017–2027
Figure 21: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Macrolides, 2017–2027
Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Aminoglycosides, 2017–2027
Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
Figure 23: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 24: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 25: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by E. Coli, 2017–2027
Figure 26: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Pseudomonas aeruginosa, 2017–2027
Figure 27: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Enterococcus spp, 2017–2027
Figure 28: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by K. pneumoniae, 2017–2027
Figure 29: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by S. aureus, 2017–2027
Figure 30: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
Figure 31: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2018–2026
Figure 32: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 33: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Acquired UTI, 2017–2027
Figure 34: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Community Acquired UTI, 2017–2027
Figure 35: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2018–2026
Figure 36: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 37: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Female, 2017–2027
Figure 38: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Male, 2017–2027
Figure 39: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2018–2026
Figure 40: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 41: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
Figure 42: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027
Figure 43: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
Figure 44: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2027
Figure 45: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 46: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Region, 2018–2026
Figure 47: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 48: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 49: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 50: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 51: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 52: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 53: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 54: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 55: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 56: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 57: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 58: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 59: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
Figure 60: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 61: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 62: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 63: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 64: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 65: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 66: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 67: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 68: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 69: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 70: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 71: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 72: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 73: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 74: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 75: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 76: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 77: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 78: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 79: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 80: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 81: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 82: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 83: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 84: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 85: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 86: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 87: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 88: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 89: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
Figure 90: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 91: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 92: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 93: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 94: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 95: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 96: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 97: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 98: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 99: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 100: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 101: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 102: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 103: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 104: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 105: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 106: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 107: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 108: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
Figure 109: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 110: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 111: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 112: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
Figure 113: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
Figure 115: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
Figure 116: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
Figure 117: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
Figure 118: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
Figure 119: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 120: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 121: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 122: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 123: Global Urinary Tract Infection Treatment Market Analysis, by Top Company Ranking, 2018
Figure 124: Global Urinary Tract Infection Treatment Market Share, by Company, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Urinary Tract Infection Treatment Market
